Re: Dr. Slamon's 10-6-11 NEJM review on Herceptin
Hi Chrisy...really curious what your onc thinks about this with regard to MM-302. I can only guess that an anthracyline attached to Trastuzumab/Her2 targeted agent would have less systemic toxicity than a standard anthracycline regimen???
|